keyword
MENU ▼
Read by QxMD icon Read
search

Ledipasvir

keyword
https://www.readbyqxmd.com/read/29233687/interferon-free-direct-acting-antiviral-therapy-for-acute-hepatitis-c-virus-infection-in-hiv-infected-individuals-a-literature-review
#1
REVIEW
Temi Lampejo, Kosh Agarwal, Ivana Carey
Dramatic rises in hepatitis C virus (HCV) coinfection rates in human immunodeficiency virus (HIV)-infected individuals have been observed recently, largely attributable to increasing recreational drug use combined with increased testing for HCV. In the era of direct-acting antiviral (DAA) therapy, treatment of acute HCV infection in HIV-infected individuals with short durations of these drugs may potentially reduce the disease and economic burden associated with HCV infection as well as reducing the likelihood of onward HCV transmission...
November 27, 2017: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29217468/availability-of-hepatitis-c-diagnostics-and-therapeutics-in-european-and-eurasia-countries
#2
Hakan Leblebicioglu, Joop E Arends, Resat Ozaras, Giampaolo Corti, Lurdes Santos, Christoph Boesecke, Andrew Ustianowski, Ann-Sofi Duberg, Simona Ruta, Nermin N Salkic, Petr Husa, Ivana Lazarevic, Juan A Pineda, Natalia Yurievna Pshenichnaya, Tengiz Tsertswadze, Mojca Matičič, Edmond Puca, Gulzhan Abuova, Judit Gervain, Ramin Bayramli, Salih Ahmeti, Mairi Koulentaki, Badreddine Kilani, Adriana Vince, Francesco Negro, Mustafa Sunbul, Dominique Salmon
BACKGROUND: Treatment with direct acting antiviral agents (DAAs) has provided sustained virological response rates in >95% of patients with chronic hepatitis C virus (HCV) infection. However treatment is costly and market access, reimbursement and governmental restrictions differ among countries. We aimed to analyze these differences among European and Eurasian countries. METHODS: A survey including 20-item questionnaire was sent to experts in viral hepatitis...
December 4, 2017: Antiviral Research
https://www.readbyqxmd.com/read/29214737/efficacy-safety-and-patient-reported-outcomes-of-ledipasvir-sofosbuvir-in-ns3-4a-protease-inhibitor-experienced-individuals-with-hepatitis-c-virus-genotype-1-and-hiv-coinfection-with-and-without-cirrhosis-anrs-hc31-softrih-study
#3
E Rosenthal, C Fougerou-Leurent, A Renault, M P Carrieri, F Marcellin, R Garraffo, E Teicher, H Aumaitre, K Lacombe, F Bailly, E Billaud, S Chevaliez, S Dominguez, M A Valantin, J Reynes, A Naqvi, L Cotte, S Metivier, V Leroy, M Dupon, T Allegre, P De Truchis, V Jeantils, J Chas, D Salmon-Ceron, P Morlat, D Neau, P Perré, L Piroth, S Pol, M Bourlière, G P Pageaux, L Alric, D Zucman, P M Girard, I Poizot-Martin, Y Yazdanpanah, F Raffi, E Le Pabic, C Tual, A Pailhé, I Amri, E Bellissant, J M Molina
OBJECTIVES: Studies evaluating the efficacy and safety of the fixed-dose combination ledipasvir (LDV)/sofosbuvir (SOF) in patients coinfected with HIV-1 and hepatitis C virus (HCV) have mainly included treatment-naïve patients without cirrhosis. We aimed to evaluate the efficacy and safety of this combination in treatment-experienced patients with and without cirrhosis. METHODS: We conducted a multicentre, open-label, double-arm, nonrandomized study in patients coinfected with HIV-1 and HCV genotype 1 with and without cirrhosis, who had good viral suppression on their antiretroviral regimens...
December 7, 2017: HIV Medicine
https://www.readbyqxmd.com/read/29197145/long-term-follow-up-of-ribavirin-free-daa-based-treatment-in-hcv-recurrence-after-orthotopic-liver-transplantation
#4
Sandra Beinhardt, Ramona Al-Zoairy, Karin Kozbial, Albert Friedrich Stättermayer, Andreas Maieron, Rudolf Stauber, Michael Strasser, Heinz Zoller, Ivo Graziadei, Susanne Rasoul-Rockenschaub, Michael Trauner, Peter Ferenci, Harald Hofer
BACKGROUND & AIMS: Excellent efficacy and safety-profile of second generation DAA-combinations improved treatment of chronic hepatitis C (HCV) as well as in HCV-recurrence after orthothopic liver transplantation (OLT). The need of ribavirin-addition is under debate as anemia and decreased renal function are prevalent in transplant-cohorts. Aim of this study was thus to assess safety and long-term efficacy of RBV-free DAA-combinations in HCV-recurrent patients after OLT. PATIENTS & METHODS: 62 OLT-recipients (male:50/81%; age:60...
December 2, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29194858/low-incidence-of-hepatitis-b-virus-reactivation-and-subsequent-hepatitis-in-patients-with-chronic-hepatitis-c-receiving-direct-acting-antiviral-therapy
#5
Akihiro Tamori, Seigo Abiru, Hirayuki Enomoto, Kiyohide Kioka, Masaaki Korenaga, Joji Tani, Masaru Enomoto, Masaya Sugiyama, Tsutomu Masaki, Norifumi Kawada, Hiroshi Yatsuhashi, Shuhei Nishiguchi, Masashi Mizokami
To determine the clinical characteristics of hepatitis B virus (HBV) reactivation in patients undergoing interferon-free anti-hepatitis C virus (HCV) therapy, we examined HBV DNA in 25 HBV co-infected patients and 765 patients with resolved HBV infection during and after treatment with direct-acting antiviral agents (DAAs). Among those with HCV genotype 1, asunaprevir plus daclatasvir was administered to 160 patients, sofosbuvir (SOF) plus ledipasvir to 438 patients, and paritaprevir plus ombitasvir and ritonavir to 25 patients...
November 30, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29192474/classical-kaposi-s-sarcoma-ks-concurrent-with-ledipasvir-sofosbuvir-therapy-for-hepatitis-c-infection-hcv
#6
Alessandra Latini, Diego Orsini, Marina Ambrifi, Manuela Colafigli, Mauro Zaccarelli, Antonio Cristaudo
No abstract text is available yet for this article.
November 30, 2017: Giornale Italiano di Dermatologia e Venereologia: Organo Ufficiale, Società Italiana di Dermatologia e Sifilografia
https://www.readbyqxmd.com/read/29183252/sexual-dysfunction-in-a-patient-taking-ledipasvir-sofosbuvir-for-the-treatment-of-hepatitis-c-a-case-report
#7
Destin U Lenz, Effie L Crutcher, Elisa M Greene
Sexual dysfunction is a bothersome side effect of several medications, though it has not yet been reported with the use of ledipasvir/sofosbuvir for the treatment of hepatitis C. However, sexual dysfunction is a potentially unrecognized side effect of ledipasvir/sofosbuvir that could result in nonadherence and treatment failure. We report a case of a 42-year-old man with a sudden onset of sexual dysfunction with the initiation of ledipasvir/sofosbuvir for the treatment of hepatitis C. The patient had no prior history or risk factors for the development of sexual dysfunction...
January 1, 2017: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/29177645/ledipasvir-sofosbuvir-for-8%C3%A2-weeks-in-non-cirrhotic-patients-with-previously-untreated-genotype-1-hcv-infection%C3%A2-%C3%A2-%C3%A2-hiv-1-co-infection
#8
Vasily Isakov, Natalia Gankina, Viacheslav Morozov, Kathryn Kersey, Sophia Lu, Anu Osinusi, Evguenia Svarovskaia, Diana M Brainard, Riina Salupere, Elena Orlova-Morozova, Konstantin Zhdanov
BACKGROUND AND OBJECTIVES: The efficacy of < 12 weeks of hepatitis C virus (HCV) treatment in patients co-infected with HCV and human immunodeficiency virus type 1 (HIV-1) has not been established. We assessed the efficacy and safety of ledipasvir-sofosbuvir for 8 weeks in HCV mono-infected and HCV/HIV-1 co-infected patients. METHODS: We enrolled patients mono-infected with genotype 1 HCV or co-infected with HCV and HIV-1 who were HCV treatment-naive and did not have cirrhosis...
November 24, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/29175627/establishment-of-robust-hcv-genotype-4d-5a-and-6a-replicon-systems
#9
Gregory Camus, Simin Xu, Bin Han, Julia Lu, Hadas Dvory-Sobol, Mei Yu, Guofeng Cheng, Michael D Miller, Brian P Doehle, Hongmei Mo
Hepatitis C Virus (HCV) is a diverse human pathogen which displays ~15% divergence at the subtype level. To facilitate development of antivirals with pan-genotype activity, we developed the first genotype 4d subgenomic replicon, as well as new replicons for genotypes 5a, and 6a. Adaptive mutations developed in these replicons differ greatly across genotypes. Their impacts on the replication capacity were tested using site-directed mutants. In the genotype 4d replicon, single mutations have moderate effect, but the double mutation NS4A-Q34R+NS5A-S232G increased the replication capacity by 161-fold...
November 22, 2017: Virology
https://www.readbyqxmd.com/read/29174546/efficacy-of-ledipasvir-and-sofosbuvir-treatment-of-hcv-infection-in-patients-coinfected-with-hbv
#10
Chun-Jen Liu, Wan-Long Chuang, I-Shyan Sheen, Horng-Yuan Wang, Chi-Yi Chen, Kuo-Chih Tseng, Ting-Tsung Chang, Benedetta Massetto, Jenny C Yang, Chohee Yun, Steven J Knox, Anu Osinusi, Gregory Camus, Deyuan Jiang, Diana M Brainard, John G McHutchison, Tsung-Hui Hu, You-Chun Hsu, Gin-Ho Lo, Chi-Jen Chu, Jyh-Jou Chen, Cheng-Yuan Peng, Ron-Nan Chien, Pei-Jer Chen
BACKGROUND & AIMS: There have been reports of reactivation of hepatitis B virus (HBV) infection during treatment of hepatitis C virus (HCV) infection with direct-acting antiviral agents. We performed a prospective study of risks and outcomes of HCV infection treatment with ledipasvir and sofosbuvir in patients with HBV infection. METHODS: We performed a phase 3b, multicenter, open-label study in Taiwan of 111 patients with HCV infection (61% HCV genotype 1, 39% HCV genotype 2 infection; 62% women, 16% with compensated cirrhosis) along with HBV infection...
November 21, 2017: Gastroenterology
https://www.readbyqxmd.com/read/29152769/sofosbuvir-peg-interferon-ribavirin-for-retreatment-of-hcv-genotype-1b-following-sofosbuvir-and-ledipasvir-failure
#11
Chetan Kalal, Akash Shukla, Ravi Mohanka, Mihir Vora, Priyesh Patel, Samir Shah
No abstract text is available yet for this article.
November 20, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29146520/patterns-of-resistance-associated-substitutions-in-patients-with-chronic-hcv-infection-following-treatment-with-direct-acting-antivirals
#12
Julia Dietz, Simone Susser, Johannes Vermehren, Kai-Henrik Peiffer, Georgios Grammatikos, Annemarie Berger, Peter Ferenci, Maria Buti, Beat Müllhaupt, Bela Hunyady, Holger Hinrichsen, Stefan Mauss, Jörg Petersen, Peter Buggisch, Gisela Felten, Dietrich Hüppe, Gaby Knecht, Thomas Lutz, Eckart Schott, Christoph Berg, Ulrich Spengler, Thomas von Hahn, Thomas Berg, Stefan Zeuzem, Christoph Sarrazin
BACKGROUND & AIMS: Little is known about substitutions that mediate resistance of HCV to direct-acting antivirals (DAAs), due to the small number of patients with treatment failure in approval studies. It is important to identify resistance patterns to select effective salvage treatments. METHODS: We performed a comprehensive analysis for resistance-associated substitutions (RASs) in HCV genes (NS3, NS5A, NS5B) targeted by DAAs. We compared NS3, NS5A, and NS5B sequences from 626 patients in Europe with DAA failure with sequences from 2322 DAA-naïve patients, infected with HCV genotypes 1-4...
November 13, 2017: Gastroenterology
https://www.readbyqxmd.com/read/29135824/shortened-8-weeks-course-of-dual-sofosbuvir-daclatasvir-therapy-in-adolescent-patients-with-chronic-hepatitis-c-infection
#13
Mortada El-Shabrawi, Alaa M Abdo, Hisham El-Khayat, Mostafa Yakoot
Recently, sofosbuvir and the fixed dose combination of sofosbuvir/ ledipasvir were approved for the treatment of chronic hepatitis C virus infection (HCV) in adolescents, 12 years old and above or weighing at least 35 kilograms. Here we present the results of a pilot single cohort of 10 consecutive adolescent patients with chronic HCV and treated with dual sofosbuvir/daclatasvir (SOF/DCV) therapy for a response-tailored duration of 8 weeks for those who achieved very rapid virologic response (vRVR) and 12 weeks for those who did not...
November 10, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/29133244/real-world-effectiveness-of-8-weeks-treatment-with-ledipasvir-sofosbuvir-in-chronic-hepatitis-c
#14
Peter Buggisch, Johannes Vermehren, Stefan Mauss, Rainer Günther, Eckart Schott, Anita Pathil, Klaus Boeker, Tim Zimmermann, Gerlinde Teuber, Heike-Pfeiffer Vornkahl, Karl-Georg Simon, Claus Niederau, Heiner Wedemeyer, Stefan Zeuzem
BACKGROUND AND AIMS: Ledipasvir/Sofosbuvir (LDV/SOF) for 8 to 24 weeks is approved for the treatment of chronic hepatitis C virus infection (HCV). In the ION-3 study 8 weeks of LDV/SOF was non-inferior to 12 weeks in previously untreated genotype 1 (GT1) patients without cirrhosis. According to the summary of product characteristics (SmPC), 8 weeks treatment may be considered in naïve non-cirrhotic GT1-patients. However, there are only limited data on the effectiveness of 8 week regimen of LDV/SOF under real-world conditions available...
November 10, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29125670/use-of-a-hepatitis-c-virus-hcv-rna-positive-donor-in-a-treated-hcv-rna-negative-liver-transplant-recipient
#15
Isabel Campos-Varela, Eliana Z Agudelo, Monika Sarkar, John P Roberts, Norah A Terrault
The shortage of livers has led most transplant centers to use extended criteria donors. Hepatitis C virus (HCV) RNA-positive donors are typically not given to patients who have cleared HCV. A 64-year-old male with chronic hepatitis C, genotype 1b was listed for LT with hepatocellular carcinoma. While on the waiting list, the patient was treated with sofosbuvir, ledipasvir, and ribavirin and achieved an HCV RNA <15 IU/mL by week 10. At week 18 of a planned 24-week treatment course, the patient underwent deceased-donor LT and received an organ from an anti-HCV-positive donor...
November 10, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29120906/efficacy-of-ledipasvir-sofosbuvir-plus-ribavirin-for-12-weeks-in-patients-with-chronic-hepatitis-c-genotype-3-and-compensated-liver-disease
#16
Stephan Moser, Karin Kozbial, Hermann Laferl, Angelika Schütz, Thomas Reiberger, Philipp Schwabl, Enisa Gutic, Cornelia Schwanke, Raphael Schubert, Julian Luhn, Tobias Lang, Michael Schleicher, Petra Steindl-Munda, Hans Haltmayer, Peter Ferenci, Michael Gschwantler
INTRODUCTION: In the era of direct-acting antivirals, hepatitis C virus (HCV) genotype (GT) 3 remains as the most difficult-to-treat HCV-GT. Currently, data on the efficacy of ledipasvir/sofosbuvir plus ribavirin (SOF/LDV+RBV) in GT3-infected patients are limited. We investigated the efficacy of this regimen in a real-life cohort from Austria. PATIENTS AND METHODS: A total of 55 patients with HCV-GT3 and compensated liver disease (20% treatment-experienced, 33% with cirrhosis, 7% with HIV coinfection) from four Austrian hepatitis centers received treatment with SOF/LDV+RBV for 12 weeks...
November 8, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29119149/sofosbuvir-ledipasvir-fixed-dose-combination-for-treatment-of-chronic-hepatitis-c-virus-infection-in-children
#17
S A Rizza, V Nehra, Z Temesgen
The United States Food and Drug Administration recently approved sofosbuvir and the fixed-dose combination of ledipasvir/sofosbuvir for the treatment of hepatitis C virus (HCV) infection in children ages 12 to 17. These are the first direct-acting antiviral treatments approved for children and adolescents with HCV. Pharmacokinetic data confirm equivalent drug exposure in this population as that found in adults during clinical trials. The efficacy and safety of these drugs has been shown in clinical trials.
August 2017: Drugs of Today
https://www.readbyqxmd.com/read/29111569/the-influence-of-immunosuppressants-on-direct-acting-antiviral-therapy-is-dependent-on-hepatitis-c-virus-genotype
#18
Alexandra Frey, Katja Piras-Straub, Andreas Walker, Jörg Timm, Guido Gerken, Kerstin Herzer
BACKGROUND: Direct-acting antivirals (DAA) have substantially increased sustained virological response rates after liver transplantation, with improved tolerance compared to interferon-based therapy. The influence of immunosuppressive agents on the efficacy of DAAs has not been clarified. METHODS: Subgenomic HCV replicons for genotype (GT) 1b, 2b, 3a and 4a were treated with the mammalian target of rapamycin (mTOR) inhibitors everolimus and sirolimus or with the calcineurin inhibitors (CNI) cyclosporine or tacrolimus, either alone or in combination with selected DAAs...
November 7, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29109851/safety-and-efficacy-of-ledipasvir-sofosbuvir-on-hepatitis-c-eradication-in-hepatitis-c-virus-human-immunodeficiency-virus-co-infected-patients
#19
Xiaoping He, Lynne Hopkins, George Everett, Willie M Carter, Cynthia SchroppDyce, Khalid Abusaada, Vincent Hsu
AIM: To evaluate the safety and efficacy of ledipasvir/sofosbuvir on hepatitis C eradication in patients with hepatitis C virus (HCV)/human immunodeficiency virus (HIV) co-infection in an urban HIV clinic. METHODS: A retrospective cohort study of 40 subjects co-infected with HIV-1 and HCV treated with the fixed-dose combination of ledipasvir and sofosbuvir for 12 wk from 2014 to 2016. All patients included were receiving antiretroviral therapy (ART) with HIV RNA values of 100 copies/mL or fewer regardless of baseline HCV RNA level...
October 28, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/29104131/treatment-of-acute-hepatitis-c-with-ledipasvir-and-sofosbuvir-in-patients-with-hematological-malignancies-allows-early-re-start-of-chemotherapy
#20
Giuseppina Brancaccio, Maria Chiara Sorbo, Ferdinando Frigeri, Viviana Rizzo, Marco Cantone, Francesco Genderini, Lavinia Fabeni, Antonio Pinto, Carlo Federico Perno, Francesca Ceccherini-Silberstein, Giovanni Battista Gaeta
No abstract text is available yet for this article.
November 2, 2017: Clinical Gastroenterology and Hepatology
keyword
keyword
40094
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"